🟢 NMRA is trading 5.3% up today on technical rebound after trial-failure selloff

NMRA is trading 5.3% up at $1.59 on a technical rebound following a sharp selloff earlier this month.

• The move appears driven by bargain hunting and technical repricing after the stock's recent capitulation following failed Phase 3 depression trials.
• There are no new fundamental announcements today, and the stock is outperforming broader indices which are currently trading lower.
• The earlier June collapse was exacerbated by news of deep workforce cuts alongside the clinical trial failure.